Steven C. Gilman
Steven C. Gilman is on the board of Vericel Corp. and 8 other companies. He previously occupied the position of Chairman, President & Chief Executive Officer at ActivBiotics, Inc., Chief Scientific Officer & Executive VP-Research at Cubist Pharmaceuticals LLC, Scientist at Wyeth Corp., Vice President & General Manager-Inflammation at Takeda Oncology Co., Biology Director at Jazz Pharmaceuticals (EUSA Pharma USA), Inc., Group Director at Pfizer (St. Louis), Principal at Connecticut College, General Manager at Inflammation Research Association, Inc. and Principal at Temple University School of Medicine.
Steven C. Gilman received a graduate degree and a doctorate from The Pennsylvania State University and an undergraduate degree from Miami University.
|08/05/2020||13,000||Disposition at $32.75 per share.||425,750|
|08/05/2020||13,000||Derivative/Non-derivative trans. at $10.63 per share.||138,190|
|07/29/2020||10,000||Disposition at $29.7 per share.||297,000|
|07/29/2020||10,000||Derivative/Non-derivative trans. at $10.63 per share.||106,300|
|07/22/2020||10,000||Disposition at $33.23 per share.||332,300|
|07/22/2020||10,000||Award at $10.63 per share.||106,300|
|06/20/2019||4,356||Derivative/Non-derivative trans. at $0 per share.||0|
|06/22/2018||2,294||Disposition at $21.5 per share.||49,321|
|06/20/2018||5,734||Derivative/Non-derivative trans. at $0 per share.||0|